Research progress of sodium-dependent glucose transporter 2 inhibitor in renal benefit
-
摘要: 钠-葡萄糖共转运蛋白2抑制剂（SGLT-2i）是一类新型的口服降糖药，其通过抑制钠-葡萄糖共转运蛋白2（SGLT-2）而降低肾糖阈，促进尿葡萄糖排泄，进而起到降低血液循环中葡萄糖水平的作用。目前，约40%糖尿病患者合并慢性肾脏病（CKD），其中很大一部分会进展至终末期肾病（ESRD）。SGLT-2i不仅具有良好的降糖作用，还能减少心血管不良事件，延缓肾病进展，在非糖尿病的CKD患者中也能观察到肾脏获益。本研究总结了SGLT-2i在肾脏方面的临床试验结果，探讨其可能的作用机制及不良反应。Abstract: Sodium-dependent glucose transporter 2 inhibitor (SGLT-2i) is a new type of oral hypoglycemic agent, which can reduce the renal glucose threshold and promote urinary glucose excretion by inhibiting sodium-dependent glucose transporter 2 (SGLT-2), and finally achieve the effect of reducing the level of glucose in blood circulation. At present, about 40% of diabetic patients have chronic kidney disease (CKD), and a large part of them will progress to end-stage renal disease (ESRD). SGLT-2i not only have a good hypoglycemic effect, but also can reduce incidence of adverse cardiovascular events and delay the progression of kidney disease, and the renal benefits can be observed even in non-diabetic patients with CKD. This study summarized the clinical trial results of SGLT-2i in kidney, and explored its possible mechanism of action and adverse reactions.
-
-
[1] International Diabetes Federation. IDF DIABETES ATLAS, 9th edition 2019[EB/OL]. https://www.diabetesatlas.org/en/https://www.diabetesatlas.org/en/
[2] 王静, 胡天晓, 许瑶. 糖尿病患者的新守护者: 浅谈钠葡萄糖共转运蛋白2抑制剂[J]. 浙江医学, 2020, 42(15): 1569-1573, 1578. doi: 10.12056/j.issn.1006-2785.2020.42.15.2020-2783 [3] BUSE J B, WEXLER D J, TSAPAS A, et al. Erratum. 2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD)[J]. Diabetes Care, 2020, 43(7): 1670. doi: 10.2337/dc20-er07
[4] ZELNIKER T A, WIVIOTT S D, RAZ I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials[J]. Lancet, 2019, 393(10166): 31-39. doi: 10.1016/S0140-6736(18)32590-X
[5] HEERSPINK H J L, KARASIK A, THURESSON M, et al. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study[J]. Lancet Diabetes Endocrinol, 2020, 8(1): 27-35. doi: 10.1016/S2213-8587(19)30384-5
[6] JARDINE M J, MAHAFFEY K W, NEAL B, et al. The canagliflozin and renal endpoints in diabetes with established nephropathy clinical evaluation (CREDENCE) study rationale, design, and baseline characteristics[J]. Am J Nephrol, 2017, 46(6): 462-472. doi: 10.1159/000484633
[7] HEERSPINK H J L, STEFÁNSSON B V, CORREA-ROTTER R, et al. Dapagliflozin in patients with chronic kidney disease[J]. N Engl J Med, 2020, 383(15): 1436-1446. doi: 10.1056/NEJMoa2024816
[8] WANNER C, LACHIN J M, INZUCCHI S E, et al. Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease[J]. Circulation, 2018, 137(2): 119-129. doi: 10.1161/CIRCULATIONAHA.117.028268
[9] NEAL B, PERKOVIC V, MATTHEWS D R. Canagliflozin and cardiovascular and renal events in type 2 diabetes[J]. N Engl J Med, 2017, 377(21): 2099. doi: 10.1080/00325481.2018.1423852
[10] PERKOVIC V, DE ZEEUW D, MAHAFFEY K W, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials[J]. Lancet Diabetes Endocrinol, 2018, 6(9): 691-704. doi: 10.1016/S2213-8587(18)30141-4
[11] MOSENZON O, WIVIOTT S D, CAHN A, et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial[J]. Lancet Diabetes Endocrinol, 2019, 7(8): 606-617. doi: 10.1016/S2213-8587(19)30180-9
[12] WANNER C H, INZUCCHI S E, ZINMAN B. Empagliflozin and progression of kidney disease in type 2 diabetes[J]. N Engl J Med, 2016, 375(18): 1801-1802. http://europepmc.org/abstract/MED/27299675
[13] PACKER M. SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: a paradigm shift in understanding their mechanism of action[J]. Diabetes Care, 2020, 43(3): 508-511. doi: 10.2337/dci19-0074
[14] NEUEN B L, OHKUMA T, NEAL B, et al. Effect of canagliflozin on renal and cardiovascular outcomes across different levels of albuminuria: data from the CANVAS program[J]. J Am Soc Nephrol, 2019, 30(11): 2229-2242. doi: 10.1681/ASN.2019010064
[15] PERKOVIC V, JARDINE M J, NEAL B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy[J]. N Engl J Med, 2019, 380(24): 2295-2306. doi: 10.1056/NEJMoa1811744
[16] NEUEN B L, YOUNG T, HEERSPINK H J L, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis[J]. Lancet Diabetes Endocrinol, 2019, 7(11): 845-854. doi: 10.1016/S2213-8587(19)30256-6
[17] CANNON C P, PRATLEY R, DAGOGO-JACK S, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes[J]. N Engl J Med, 2020, 383(15): 1425-1435. doi: 10.1056/NEJMoa2004967
[18] VALLON V, THOMSON S C. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition[J]. Diabetologia, 2017, 60(2): 215-225. doi: 10.1007/s00125-016-4157-3
[19] BRADY J A, HALLOW K M. Model-based evaluation of proximal sodium reabsorption through SGLT2 in health and diabetes and the effect of inhibition with canagliflozin[J]. J Clin Pharmacol, 2018, 58(3): 377-385. doi: 10.1002/jcph.1030
[20] ZHANG Z Q, NI L H, ZHANG L, et al. Empagliflozin regulates the AdipoR1/p-AMPK/p-ACC pathway to alleviate lipid deposition in diabetic nephropathy[J]. Diabetes Metab Syndr Obes, 2021, 14: 227-240. doi: 10.2147/DMSO.S289712
[21] 王丽晖, 吴广礼. 钠-葡萄糖共转运蛋白2抑制剂对糖尿病肾脏病保护作用的研究进展[J]. 中国中西医结合肾病杂志, 2020, 21(10): 931-934. doi: 10.3969/j.issn.1009-587X.2020.10.029 [22] PIRKLBAUER M, BERND M, FUCHS L, et al. Empagliflozin inhibits basal and IL-1β-mediated MCP-1/CCL2 and endothelin-1 expression in human proximal tubular cells[J]. Int J Mol Sci, 2020, 21(21): E8189. doi: 10.3390/ijms21218189
[23] HEERSPINK H J L, PERCO P, MULDER S, et al. Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease[J]. Diabetologia, 2019, 62(7): 1154-1166. doi: 10.1007/s00125-019-4859-4
[24] HANSELL P, WELCH W J, BLANTZ R C, et al. Determinants of kidney oxygen consumption and their relationship to tissue oxygen tension in diabetes and hypertension[J]. Clin Exp Pharmacol Physiol, 2013, 40(2): 123-137. doi: 10.1111/1440-1681.12034
[25] MARTON A, KANEKO T, KOVALIK J P, et al. Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation[J]. Nat Rev Nephrol, 2021, 17(1): 65-77. doi: 10.1038/s41581-020-00350-x
[26] O'NEILL J, FASCHING A, PIHL L, et al. Acute SGLT inhibition normalizes O2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats[J]. Am J Physiol Renal Physiol, 2015, 309(3): F227-F234. doi: 10.1152/ajprenal.00689.2014
[27] TOMITA I, KUME S, SUGAHARA S, et al. SGLT2 inhibition mediates protection from diabetic kidney disease by promoting ketone body-induced mTORC1 inhibition[J]. Cell Metab, 2020, 32(3): 404-419.e6. doi: 10.1016/j.cmet.2020.06.020
[28] ROSSERT J, FROISSART M. Role of Anemia in progression of chronic kidney disease[J]. Semin Nephrol, 2006, 26(4): 283-289. doi: 10.1016/j.semnephrol.2006.05.004
[29] MARATHIAS K P, LAMBADIARI V A, MARKAKIS K P, et al. Competing effects of renin angiotensin system blockade and sodium-glucose cotransporter-2 inhibitors on erythropoietin secretion in diabetes[J]. Am J Nephrol, 2020, 51(5): 349-356. doi: 10.1159/000507272
[30] CONSOLI A, FORMOSO G, BALDASSARRE M P A, et al. A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment[J]. Expert Opin Drug Saf, 2018, 17(3): 293-302. doi: 10.1080/14740338.2018.1428305
[31] ERONDU N, DESAI M, WAYS K, et al. Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program[J]. Diabetes Care, 2015, 38(9): 1680-1686. doi: 10.2337/dc15-1251
[32] HENRY R R, THAKKAR P, TONG C, et al. Efficacy and safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes[J]. Diabetes Care, 2015, 38(12): 2258-2265. doi: 10.2337/dc15-1730
[33] TOULIS K A, BILEZIKIAN J P, THOMAS G N, et al. Initiation of dapagliflozin and treatment-emergent fractures[J]. Diabetes Obes Metab, 2018, 20(4): 1070-1074. doi: 10.1111/dom.13176
[34] KOHAN D E, FIORETTO P, TANG W H, et al. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control[J]. Kidney Int, 2014, 85(4): 962-971. doi: 10.1038/ki.2013.356
[35] WIVIOTT S D, RAZ I, BONACA M P, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med, 2019, 380(4): 347-357. doi: 10.1056/NEJMoa1812389
[36] BILEZIKIAN J P, WATTS N B, USISKIN K, et al. Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin[J]. J Clin Endocrinol Metab, 2016, 101(1): 44-51. doi: 10.1210/jc.2015-1860
[37] YABE D, YASUI A, JI L N, et al. Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: Pooled analysis of phase Ⅰ-Ⅲ clinical trials[J]. J Diabetes Investig, 2019, 10(2): 418-428. doi: 10.1111/jdi.12910
[38] SUNG J, PADMANABHAN S, GURUNG S, et al. SGLT2 inhibitors and amputation risk: Real-world data from a diabetes foot wound clinic[J]. J Clin Transl Endocrinol, 2018, 13: 46-47. http://www.sciencedirect.com/science/article/pii/S221462371830036X
[39] LI D D, WANG T S, SHEN S, et al. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials[J]. Diabetes Obes Metab, 2017, 19(3): 348-355. http://smartsearch.nstl.gov.cn/paper_detail.html?id=5b726d4df56dc74bd3f2bb05de3fe0c1
[40] CONSOLI A, FORMOSO G, BALDASSARRE M P A, et al. A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment[J]. Expert Opin Drug Saf, 2018, 17(3): 293-302. http://europepmc.org/abstract/MED/29334278
-
期刊类型引用(9)
1. 颅内支架价值评估专家共识. 中国医疗设备. 2024(08): 1-10 . 
百度学术
2. 高永开，杜伟. 支架辅助弹簧圈栓塞术治疗急性期颅内破裂宽颈动脉瘤的临床安全性及有效性. 临床医学研究与实践. 2022(26): 66-69 . 百度学术
3. 罗妙泉，王以舟，陈连辉. LVIS密网支架辅助弹簧圈栓塞治疗颅内宽颈小动脉瘤的临床研究. 海南医学. 2021(05): 610-613 . 百度学术
4. 陈洋，李琳坤. 双LVIS支架辅助弹簧圈栓塞治疗颅内宽颈动脉瘤的安全性和有效性. 临床医学研究与实践. 2021(10): 56-58 . 百度学术
5. 张子君. LVIS支架辅助弹簧圈栓塞在颅内宽颈动脉瘤中的临床应用效果. 医学理论与实践. 2021(09): 1514-1515 . 百度学术
6. 易田康，王政，伍业，伍博. 双微导管技术及LVIS支架辅助栓塞术治疗急性期颅内宽颈动脉瘤的疗效及对患者血清SICAM-1水平与神经功能的影响. 海南医学. 2021(09): 1106-1109 . 百度学术
7. 陈步翰，唐永生，何博源. 单纯弹簧圈栓塞与LVIS支架辅助弹簧圈栓塞治疗颅内破裂宽颈动脉瘤的疗效比较. 现代实用医学. 2021(04): 549-551 . 百度学术
8. 田志华，李敏，黄可丰，段海锋，张浩，茹小红. Solitaire支架与LVIS/LVISjr支架置入辅助弹簧圈栓塞治疗颅内动脉瘤的临床效果比较. 中国临床实用医学. 2021(02): 6-9 . 百度学术
9. 王永祥，杨成宝，陈春光. 颅内未破裂动脉瘤介入治疗效果及术后发生微小脑梗死的影响因素. 宁夏医科大学学报. 2021(12): 1247-1251 . 百度学术
其他类型引用(0)
计量
- 文章访问数: 325
- HTML全文浏览量: 189
- PDF下载量: 25
- 被引次数: 9
下载:
苏公网安备 32100302010246号